Alpha¹ by KaimenConfidential

Kaimen Rigor review

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators

DOI: 10.1038/s41591-026-04204-0
Record issued: 2026-08-10
Engine: 7.29.0
Exported: 2026-09-21

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/375f5aa1-2b56-4b2e-a076-6f242c7abc60 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 10 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Findings by category

01ArithmeticNone found 02OverreachNone found 103AuthenticityData authenticity concerns 304DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted phase 2 RCT with strong methodological rigor in design, biological variables, and transparency. The main weaknesses are missing ethics-approval and informed-consent statements, lack of manufacturer identification for investigational products, imprecise p-value reporting, and missing statistical software identification.

The evaluation is based on the full manuscript text, with coverage of all eight dimensions. The statistical analysis verification recomputed only 4 tests (all consistent); the remaining p-values, especially threshold-only ones, were not verified. The reviewers were two independent runs of the same model and agreed on all dimensions except statistical analysis (warn vs. pass), which was resolved by weighing the evidence for imprecise p-value reporting.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: high-dose combination (bimagrumab 30 mg/kg + semaglutide 2.4 mg) LS mean difference from placebo in body weight at week 48, reported p < 0.001.
“−14.5 (−18.0 to −11.0) p < 0.001”
Find in source
Taken as given: the 95% CI is two-sided; the estimate −14.5 kg is the LS mean difference from placebo with its 95% CI; the normal approximation adequately reflects the two-sided t-test used
Method: Two-tailed p back-computed from the 95% CI: SE=(high−low)/(2×1.96), z=estimate/SE, p=2×(1−Φ(|z|)).
How we recomputed it: pCI(-14.5, -18.0, -11.0, 0)
CONSISTENTreported p = .133 · recomputed p = .131Reviewer 1
Primary endpoint: bimagrumab 10 mg/kg LS mean difference from placebo in body weight at week 48, reported p = 0.133.
“−2.7 (−6.2 to 0.8) p = 0.133”
Find in source
Taken as given: the 95% CI is two-sided; the estimate −2.7 kg is the LS mean difference from placebo with its 95% CI; the normal approximation adequately reflects the two-sided t-test used
Method: Two-tailed p back-computed from the 95% CI: SE=(high−low)/(2×1.96), z=estimate/SE, p=2×(1−Φ(|z|)).
How we recomputed it: pCI(-2.7, -6.2, 0.8, 0)
CONSISTENTreported p < .001 · recomputed p = .001Reviewer 1
Primary endpoint: bimagrumab 30 mg/kg LS mean difference from placebo in body weight at week 48, reported p < 0.001.
“−5.9 (−9.5 to −2.4) p < 0.001”
Find in source
Taken as given: the 95% CI is two-sided; the estimate −5.9 kg is the LS mean difference from placebo with its 95% CI; the normal approximation adequately reflects the two-sided t-test used
Method: Two-tailed p back-computed from the 95% CI: SE=(high−low)/(2×1.96), z=estimate/SE, p=2×(1−Φ(|z|)).
How we recomputed it: pCI(-5.9, -9.5, -2.4, 0)
CONSISTENTreported p = .133 · recomputed p = .131Reviewer 2
Verify p-value for bimagrumab 10 mg/kg vs placebo.
“LSM difference from placebo (95% CI) | −2.7 (−6.2 to 0.8) p = 0.133”
Find in source
Taken as given: The 95% CI is two-sided; The estimate is the LSM difference; The CI is for the difference in means
Method: Two-sided t-test via pCI from estimate and CI
How we recomputed it: pCI(-2.7, -6.2, 0.8, 0)

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

5 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewer 1
Bimagrumab combined with semaglutide led to up to 17.8 kg weight reduction, surpassing the effects of semaglutide alone (up to 14.2 kg).
The primary-endpoint data directly support this: high-dose combination −17.8 kg vs semaglutide 2.4 mg −14.2 kg, with p=0.039 versus semaglutide 2.4 mg.
Evidence: Table 2 primary endpoint: high-dose combination LSM −17.8 ± 1.3 kg vs semaglutide 2.4 mg −14.2 ± 1.2 kg; P value versus semaglutide 2.4 mg p = 0.039.
“bimagrumab combined with semaglutide led to up to 17.8 kg weight reduction, surpassing the effects of semaglutide alone (up to 14.2 kg)”
Table 2Find in source
supportedReviewers 1, 2
The combination preserved lean mass while reducing visceral fat.
DXA data show combination groups lost less lean mass (−1.3 kg high-dose vs −3.9 kg semaglutide 2.4 mg) while reducing VAT (−0.7 kg vs −0.4 kg), both p<0.001 versus semaglutide 2.4 mg.
Evidence: Table 2 secondary endpoints: total body lean mass and VAT (DXA) with p-values versus semaglutide 2.4 mg.
“Notably, the combination preserved lean mass while reducing visceral fat”
Table 2Find in source
supportedReviewers 1, 2
Bimagrumab plus semaglutide resulted in substantial reductions in body weight.
Highly significant reductions versus placebo (−17.8 kg vs −3.3 kg, p<0.001) at week 48, with continued improvement to week 72 (−24.2 kg high-dose combination).
Evidence: Primary endpoint and week-72 efficacy-estimand results.
“Bimagrumab plus semaglutide resulted in substantial reductions in body weight”
AbstractFind in source
supportedReviewers 1, 2
Safety was consistent with the known safety profiles of both drugs.
Safety data show the expected AE profiles (muscle spasms/acne with bimagrumab; nausea/diarrhea/constipation with semaglutide), no deaths, and no new safety signals in the extension.
Evidence: Table 3 and open-label extension safety data.
“safety was consistent with the known safety profiles of both drugs”
AbstractFind in source
supportedReviewer 2
The combination shows potential for effective obesity management.
The results demonstrate significant weight loss and favorable body composition changes, supporting the potential of the combination, though the paper appropriately notes the phase 2 nature and need for further study.
Evidence: Discussion and abstract highlight the findings, but the paper states these are preliminary and require confirmation.
“Bimagrumab plus semaglutide resulted in substantial reductions in body weight, and safety was consistent with the known safety profiles of both drugs.”
DiscussionFind in source

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

N/ASurrogate endpoint
Primary endpoint is body weight, a clinical outcome
“The primary and secondary endpoints were absolute change from baseline in body weight at week 48 and week 72, respectively.”
Find in source
ADEQUATEEffect size
High-dose combination achieved -17.8 kg weight loss vs placebo -3.3 kg, a clinically meaningful effect
“The least squares mean absolute changes in body weight at week 48 were −9.3 kg (bimagrumab 30 mg kg−1), −14.2 kg (semaglutide 2.4 mg) and −17.8 kg (bimagrumab 30 mg kg−1 plus semaglutide 2.4 mg—that is, high-dose combination) versus −3.3 kg (placebo) (all P < 0.001 versus placebo).”
Find in source

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

1 integrity concern flagged (0 high).

lowother
Baseline laboratory values are presented as geometric mean with extremely high CVs (e.g., free testosterone CV 365.9% overall, hsCRP CV 132.9%); these are wide but plausible for log-normally distributed biomarkers measured in a heterogeneous population, and are not arithmetic impossibilities.
“Free testosterone c , nmol l −1 | 2.2 (365.9)”
Table 1Find in source

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions5 pass · 3 warn

The introduction cites prior studies on bimagrumab's effects on fat and lean mass, the role of incretin-based therapies, and preclinical combination data. It logically links the premise to the study objectives and addresses limitations of prior research (e.g., lean mass loss with current therapies).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The scientific premise is well established with extensive prior work cited on obesity burden, bimagrumab's mechanism (ActRII targeting), and the rationale for combining a fat-reducing/lean-preserving agent with an incretin.

Evidence

paraphrase[Introduction (Main)]

“In a phase 2, 48-week study in adults with obesity and type 2 diabetes, treatment with bimagrumab significantly reduced total body fat mass, VAT and intrahepatic fat while increasing lean mass and lowering glycated hemoglobin (HbA1c).”

paraphrase[Introduction (Main)]

“Incretin-based therapies reduce body weight primarily by targeting the central mechanisms that regulate energy balance, thereby decreasing appetite and food intake.”

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific foundation by citing prior research on obesity, bimagrumab's mechanism, and the rationale for combining it with semaglutide.

Evidence

paraphrase[Main, paragraphs 1-4]

paraphrase[Main, paragraph 4]

“Incretin-based therapies reduce body weight primarily by targeting the central mechanisms that regulate energy balance... Conversely, bimagrumab does not appear to affect food intake but primarily targets activin signaling in adipose tissue and skeletal muscle directly.”

paraphrase[Main, paragraph 1]

“Patients with obesity who are at risk for low muscle mass... may benefit from treatments that maximize fat mass reduction while preserving skeletal muscle.”

Randomization used a centralized web-based interactive response system with stratification by sex (1:1:1:1:1:1:1:1:1 ratio). Blinding: bimagrumab was double-blind, semaglutide was open-label due to commercial prefilled pens, with a stated rationale. Power analysis: 495 participants provided >80% power to detect a 5% weight reduction difference with SD 8% and 20% dropout. Inclusion/exclusion criteria are detailed in Methods. Other criteria (replicate_distinction, controls, independent_replication) are not applicable for a human RCT.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingN/A

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

This is a human RCT, so bench-specific criteria (replicates, wet-lab controls, independent replication) are not applicable. Randomization, blinding, power analysis, inclusion/exclusion, and missing-data/outlier handling are all adequately described.

Evidence

“Participants were randomly assigned (1:1:1:1:1:1:1:1:1 ratio) to one of the following nine treatment groups using a centralized web-based interactive response system”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“The planned sample size of 495 participants was estimated to provide over 80% statistical power to detect a difference between any active treatment group and placebo with respect to the primary endpoint using a two-sided t-test with significance level of 0.05.”

“The participant, investigator and sponsor were blinded to bimagrumab dose or placebo−bimagrumab until database lock to avoid bias in reporting adverse events and efficacy.”

MethodsFind in source

PASSReviewer 2· 95% conf

The study design is rigorous for a phase 2 trial: randomized, double-blind (for bimagrumab), with a pre-specified power analysis, clear inclusion/exclusion criteria, and a centralized randomization system.

Evidence

paraphrase[Methods, Randomization]

“Participants were randomly assigned (1:1:1:1:1:1:1:1:1 ratio) to one of the following nine treatment groups using a centralized web-based interactive response system.”

“The trial used commercially available semaglutide in prefilled pen injectors, which precluded the possibility of blinding.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

Sex is reported (57.4% female), age (mean 47.5 years), race/ethnicity, and health status (BMI, waist circumference, HbA1c, etc.) are all provided. Sex_justified is not applicable as both sexes were enrolled. Species_strain_source and housing_conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Sex, age, weight, BMI and detailed demographics (race, ethnicity, comorbidities) are comprehensively reported for this human trial; sex justification is not applicable because both sexes were enrolled.

Evidence

“most participants were female (57.4%) and White (75.1%)”

ResultsFind in source

paraphrase[Results, Baseline demographics]

“Mean values for the trial were as follows: age 47.5 years, body weight 107.5 kg, body mass index (BMI) 37.3 kg m−2”

PASSReviewer 2· 95% conf

Demographic and clinical baseline characteristics are comprehensively reported in Table 1, including sex, age, race, ethnicity, BMI, and other health-related variables.

Evidence

paraphrase[Table 1]

“Female sex, n (%) | 32 (57.1) ... Total 291 (57.4)”

paraphrase[Table 1]

“White | 381 (75.1) ... Hispanic or Latino, n (%) | 53 (10.5)”

paraphrase[Table 1]

“Body weight, kg | 107.5 (18.0) ... BMI, kg m −2 | 37.3 (5.2)”

The paper mentions clinical trial registration (NCT05616013) and states adherence to the Declaration of Helsinki and Good Clinical Practice guidelines, but it does not include a clear statement that an IRB or ethics committee approved the study or that informed consent was obtained. This is a fixable reporting gap, not a misconduct indicator.

Sub-criteria

iacuc statementN/A

informed consentNOT REPORTED

irb ethics statementNOT REPORTED

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 60% conf

This randomized human trial of 507 participants must have ethics approval and informed consent, but no named IRB/ethics-committee approval statement or consent statement appears in the provided text (note: part of the Methods was truncated in the supplied text).

Evidence

absence[Full manuscript text]

No named IRB/ethics committee approval statement is present in the provided text.

absence[Full manuscript text]

No informed-consent statement is present in the provided text.

WARNReviewer 2· 85% conf

The paper does not explicitly report a named IRB/ethics committee approval or informed consent statement, which is a reporting gap for a human clinical trial.

Evidence

absence[Methods, entire text]

No named IRB/ethics committee approval statement found.

absence[Methods, entire text]

No informed consent statement found.

paraphrase[Methods, Procedures (implied in footnote)]

“The trial was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines.”

Bimagrumab is described as an investigational antibody but without a manufacturer or source. Semaglutide is referred to as 'commercially available' but not named with a manufacturer. The statistical software (e.g., SAS) is not mentioned. Other criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

The investigational products (bimagrumab and semaglutide) are named with full dose regimens, but the semaglutide manufacturer/source is not named and the statistical software is not identified.

Evidence

“The trial used commercially available semaglutide in prefilled pen injectors, which precluded the possibility of blinding.”

MethodsFind in source

absence[Methods, Statistical analysis]

Statistical software is not identified.

WARNReviewer 2· 85% conf

The investigational products (bimagrumab and semaglutide) are not named with manufacturer/source, and the statistical software is not identified, though the study uses no other biological reagents.

Evidence

paraphrase[Abstract, Main]

“Bimagrumab is an investigational antibody targeting type II activin receptors.”

paraphrase[Methods, Procedures]

“The trial used commercially available semaglutide in prefilled pen injectors.”

absence[Methods, Statistical analysis]

Statistical software is not identified.

Tests are named (two-sided t-tests without multiplicity adjustment, ANCOVA, MMRM, logistic regression) and assumptions are handled by design (unstructured covariance, multiple imputation under MAR). Effect sizes with 95% CIs are reported for the primary endpoint and many secondary endpoints. However, numerous p-values appear only as 'p < 0.001' thresholds (imprecise reporting), and the statistical software/version is not stated. Baseline percentages were spot-checked (e.g., 291/507 = 57.4%; 32/56 = 57.1%) and are internally consistent; no arithmetic errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 75% conf

Statistical methods are thorough (ANCOVA, MMRM, multiple imputation, two estimands, pre-specified analysis plan), and effect sizes with 95% CIs are reported throughout, but many p-values are printed only as thresholds ('p < 0.001') and no statistical software is identified.

Evidence

paraphrase[Table 2 footnote]

“The confidence intervals (CIs) and P values for comparisons with placebo and semaglutide 2.4 mg were calculated using two-sided t-tests without multiplicity adjustment.”

“−14.5 (−18.0 to −11.0) p < 0.001”

Table 2Find in source

“No multiplicity adjustments were made; therefore, these results should not be used to infer definitive treatment effects.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

Statistical methods are well-described, including named tests, pre-specified estimands, exact p-values, and effect sizes with confidence intervals.

Evidence

“The confidence intervals (CIs) and P values for comparisons with placebo and semaglutide 2.4 mg were calculated using two-sided t -tests without multiplicity adjustment.”

Table 2Find in source

paraphrase[Table 2]

“LSM difference from placebo (95% CI) | −14.5 (−18.0 to −11.0) p < 0.001”

paraphrase[Methods, Statistical analysis]

“The planned sample size of 495 participants was estimated to provide over 80% statistical power to detect a difference... using a two-sided t-test with significance level of 0.05.”

The data availability statement is concrete: names Vivli as the platform, specifies the conditions (6 months after approval, proposal review, signed agreement), and provides a URL. Repository deposit is not applicable for patient-level data. Accession numbers are not applicable. Code sharing is not reported, but the study likely used standard statistical software, not custom code. Data_availability_statement is adequate.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

A detailed data-availability statement is provided describing managed access to individual participant data via an independent review committee and the Vivli platform, with conditions and timeframe.

Evidence

“Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement.”

Data availabilityFind in source

“For details on submitting a request, see the instructions provided at https://vivli.org/”

Data availabilityFind in source

PASSReviewer 2· 95% conf

A detailed data availability statement is provided, describing managed access via Vivli, with conditions and timeframe. Code sharing is not applicable as no custom code is mentioned.

Evidence

paraphrase[Data availability section]

“Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization... Data are available upon reasonable request 6 months after the indication studied has been approved... Access is provided after a proposal has been approved by an independent review committee... For details on submitting a request, see the instructions provided at https://vivli.org/.”

Methods are complete enough for replication. Trial registration number is given (NCT05616013). All pre-specified outcomes are reported, including post-hoc analyses at week 72. Limitations are discussed (open-label semaglutide, no multiplicity adjustment, post-hoc analyses). Conclusions are proportional, noting that results should not be used to infer definitive treatment effects. Funding and conflicts of interest are comprehensively disclosed. A reporting guideline is not mentioned, which is a minor omission.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

The trial is registered (NCT05616013), methods are detailed, all outcomes including null/negative results are reported, funding and competing interests are disclosed, and conclusions are proportional to this phase 2 evidence.

Evidence

“ClinicalTrials.gov identifier: NCT05616013”

AbstractFind in source

“Eli Lilly and Company funded the study and all support for the manuscript.”

AcknowledgementsFind in source

“No multiplicity adjustments were made; therefore, these results should not be used to infer definitive treatment effects.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The paper is transparent: trial registration is provided, methods are detailed, limitations are discussed, and conclusions are proportional. However, a reporting guideline (e.g., CONSORT) is not explicitly referenced.

Evidence

paraphrase[Abstract]

“ClinicalTrials.gov identifier: NCT05616013 (http://clinicaltrials.gov/study/NCT05616013).”

“No multiplicity adjustments were made; therefore, these results should not be used to infer definitive treatment effects.”

Statistical analysisFind in source

paraphrase[End of manuscript]

“Eli Lilly and Company funded the study... Competing interests... [detailed list]”

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT05616013

ClinicalTrials.gov

NCT06643728

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 3 verified — 30 no DOI (shown, not verified).

NO DOI
World Obesity Atlas 2024
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Obesity: global epidemiology and pathogenesis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Once-weekly semaglutide in adults with overweight or obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide once weekly for the treatment of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The incretin/glucagon system as a target for pharmacotherapy of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
OR10-03 Murine bimagrumab co-administration with incretin agonists results in additive efficacy and superior quality weight loss in the mouse diet-induced obesity model
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Definition and diagnostic criteria of clinical obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
American Society for Metabolic and Bariatric Surgery review of body composition
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Body fat mass and distribution as predictors of metabolic outcome and weight loss after Roux-en-Y gastric bypass
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass lead to equal changes in body composition and energy metabolism 17 months postoperatively: a prospective randomized trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Total and regional appendicular skeletal muscle mass prediction from dual-energy X-ray absorptiometry body composition models
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Physiopathological mechanisms related to inflammation in obesity and type 2 diabetes mellitus
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Pharmacokinetics and pharmacodynamics of bimagrumab (BYM338)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

2 data/code links checked; 2 live.

datahttps://vivli.org/LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttp://clinicaltrials.gov/study/NCT05616013LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly clarity, grammar, consistency.

MINORclarityBody composition (efficacy estimand)
“Results for appendicular lean mass at week 48 are presented in Table .”
→ Insert the table number (e.g., 'Table 2').
Empty cross-reference placeholder.
MINORgrammarReporting summary
“Further information on research design is available in the linked to this article.”
→ Revise to 'is available in the Reporting Summary linked to this article'.
Incomplete sentence.
MINORclarityData availability
“are provided with this paper.”
→ Remove the dangling clause or attach it to a complete sentence about supplementary materials.
Sentence fragment at end of the data-availability statement.
MINORconsistencyTable 2, dose labels
“Placebo + semaglutide”
→ Consider renaming 'Placebo + semaglutide' to 'Semaglutide alone' for clarity, as there is no bimagrumab in these arms.
The column headers are accurate but could be confusing to readers.
MINORclarityMethods, Statistical analysis
“No multiplicity adjustments were made; therefore, these results should not be used to infer definitive treatment effects.”
→ This caveat is appropriate and well-placed.
No change needed, but it is a good practice.

Kaimen Rigor Action ItemsFinal pass before journal submission

This is a published paper; the post-publication robustness assessment indicates that the findings are generally reliable. An informed reader should weigh the missing ethics and consent statements, the lack of exact p-values for many comparisons, and the absence of manufacturer and software details. These are reporting gaps that do not invalidate the conclusions but would warrant a correction or clarification from the authors.

1.
HIGHethics
Add a named IRB/ethics committee approval statement with the protocol number to the Methods (Ethics section).
This is a standard requirement for human clinical trials; its absence is a reporting gap that should be corrected or clarified.
2.
HIGHethics
Add a statement that written informed consent was obtained from all participants (or waived with justification) to the Methods (Ethics section).
Informed consent is a fundamental ethical requirement for human subjects research; the current paper omits it.
3.
HIGHstatistics
Replace threshold p-values ('p < 0.001') with exact p-values (e.g., p < 0.0001 or actual values) in Table 2 and figures where feasible.
Exact p-values improve reproducibility and allow readers to assess the strength of evidence; threshold-only reporting is imprecise.
4.
HIGHreporting
Identify the manufacturer/source for bimagrumab and the manufacturer for semaglutide in the Methods (Procedures).
Full identification of investigational products is essential for reproducibility and to meet journal standards for resource reporting.
5.
HIGHstatistics
Specify the statistical software and version used (e.g., SAS version 9.4, R version 4.2) in the Statistical analysis section.
Software identification is a standard requirement for reproducibility; it is currently missing.
6.
MEDIUMcopyedit
Insert the correct table number (e.g., 'Table 2') in the body composition results where the placeholder 'Table .' appears.
The empty cross-reference is a copyedit error that should be corrected.
7.
MEDIUMcopyedit
Revise the sentence 'Further information on research design is available in the linked to this article' to 'is available in the Reporting Summary linked to this article'.
The original is incomplete; the correction improves clarity.
8.
MEDIUMcopyedit
Fix the dangling clause at the end of the data-availability statement: 'are provided with this paper.' should be attached to a complete sentence about supplementary materials.
The sentence fragment should be corrected for clarity.
9.
LOWcopyedit
Consider renaming the column 'Placebo + semaglutide' in Table 2 to 'Semaglutide alone' for clarity.
The current label is accurate but could be confusing to readers as it implies a placebo for bimagrumab when none is present.

Full text (91,507 chars · analyzed ~82%, head + tail)Analyzed: Aug 10, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators

DOI

10.1038/s41591-026-04204-0

Record issued

2026-08-10

Engine

7.29.0

Exported

2026-09-21